Bokf Na reduced its position in Danaher Corporation (NYSE:DHR – Free Report) by 9.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 29,430 shares of the conglomerate’s stock after selling 3,009 shares during the quarter. Bokf Na’s holdings in Danaher were worth $6,737,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Elevated Capital Advisors LLC acquired a new position in shares of Danaher during the fourth quarter worth about $26,000. JPL Wealth Management LLC acquired a new position in shares of Danaher during the third quarter worth about $25,000. WFA of San Diego LLC acquired a new position in shares of Danaher during the second quarter worth about $26,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Danaher during the third quarter worth about $27,000. Finally, Financial Life Planners acquired a new position in shares of Danaher during the third quarter worth about $32,000. 79.05% of the stock is owned by institutional investors and hedge funds.
Danaher Price Performance
Shares of NYSE DHR opened at $174.85 on Thursday. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a twelve month low of $172.06 and a twelve month high of $242.80. The stock has a 50 day moving average of $191.92 and a two-hundred day moving average of $212.77. The stock has a market cap of $123.75 billion, a P/E ratio of 33.82, a P/E/G ratio of 2.33 and a beta of 0.81.
Danaher Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. Danaher’s payout ratio is currently 30.95%.
Insiders Place Their Bets
In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the completion of the sale, the executive vice president owned 5,099 shares in the company, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.80% of the company’s stock.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the company. Leerink Partners boosted their price objective on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research report on Friday, January 16th. Wall Street Zen downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Evercore boosted their price objective on Danaher from $225.00 to $232.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 21st. Rothschild & Co Redburn set a $205.00 target price on Danaher in a research note on Friday, April 17th. Finally, Jefferies Financial Group restated a “buy” rating and set a $245.00 target price on shares of Danaher in a research note on Tuesday, April 21st. Eighteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $240.70.
View Our Latest Report on Danaher
About Danaher
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Recommended Stories
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
